Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salt – page 27

330 clinical trials in Salt, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salt at a glance
330
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

330 trials in Salt

Open in trial search

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Not recruiting

Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Hormone receptor positive breast cancer

Not recruiting

Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Liver disorder

Not recruiting

Study on Zinc Acexamate for Patients with Advanced Chronic Liver Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zinc Acexamate
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Salt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing-remitting multiple sclerosis and its treatment approaches, including comparative studies of novel therapies and established medications.

  • Treatment Comparisons
  • Long-term Safety Studies
  • Disease Progression Management

Multiple innovative therapies are being evaluated to improve patient outcomes and reduce disease progression.

02 Progressive MS Studies

Dedicated research into Primary Progressive Multiple Sclerosis (PPMS), exploring new therapeutic options through targeted treatment approaches.

  • Disability Progression
  • Novel Treatment Mechanisms
  • Long-term Effectiveness

Studies focus on developing treatments to delay disability progression in PPMS patients.

03 Specialized Conditions

Research addressing specific medical conditions including severe primary hand hyperhidrosis and pregnancy-related conditions such as nausea and vomiting.

  • Topical Treatments
  • Pregnancy-related Conditions
  • Quality of Life Improvements

Clinical investigations aim to enhance treatment options and patient comfort across various conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.